A Badran

Dual GLP-1/glucagon receptor agonists in metabolic dysfunction–associated steatotic liver disease: a meta-analysis of randomized controlled trials

Metabolic dysfunction–associated steatotic liver disease (MASLD) affects approximately one-third of the global population. We aimed to evaluate the efficacy and safety of dual glucagon-like peptide-1 and glucagon receptor agonists (GLP-1/Gcg RAs) in patients with MASLD. PubMed, W...